Terazosin: Difference between revisions

Jump to navigation Jump to search
m (Protected "Terazosin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Line 3: Line 3:
{{CMG}}
{{CMG}}


{{EH}}
 


==Overview==
==Overview==
Line 18: Line 18:


[[Category:Drugs]]
[[Category:Drugs]]
{{SIB}}
 
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 16:43, 20 August 2012

WikiDoc Resources for Terazosin

Articles

Most recent articles on Terazosin

Most cited articles on Terazosin

Review articles on Terazosin

Articles on Terazosin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Terazosin

Images of Terazosin

Photos of Terazosin

Podcasts & MP3s on Terazosin

Videos on Terazosin

Evidence Based Medicine

Cochrane Collaboration on Terazosin

Bandolier on Terazosin

TRIP on Terazosin

Clinical Trials

Ongoing Trials on Terazosin at Clinical Trials.gov

Trial results on Terazosin

Clinical Trials on Terazosin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Terazosin

NICE Guidance on Terazosin

NHS PRODIGY Guidance

FDA on Terazosin

CDC on Terazosin

Books

Books on Terazosin

News

Terazosin in the news

Be alerted to news on Terazosin

News trends on Terazosin

Commentary

Blogs on Terazosin

Definitions

Definitions of Terazosin

Patient Resources / Community

Patient resources on Terazosin

Discussion groups on Terazosin

Patient Handouts on Terazosin

Directions to Hospitals Treating Terazosin

Risk calculators and risk factors for Terazosin

Healthcare Provider Resources

Symptoms of Terazosin

Causes & Risk Factors for Terazosin

Diagnostic studies for Terazosin

Treatment of Terazosin

Continuing Medical Education (CME)

CME Programs on Terazosin

International

Terazosin en Espanol

Terazosin en Francais

Business

Terazosin in the Marketplace

Patents on Terazosin

Experimental / Informatics

List of terms related to Terazosin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Synonyms / Brand Names: Terazosin HCl, Terazosin hydrochloride, Terazosina, Terazosine, Terazosinum, Trazosin HCl, Abbott 45975, Blavin, Flumarc, Fosfomic, Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard, Vasomet, Vicard

Dosing and Administration

Benign prostatic hyperplasia

  • Initial dose: 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded as an initial dose. Patients should be closely followed during initial administration in order to minimize the risk of severe hypotensive response.

Hypertension

  • Initial dose: 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. This initial dosing regimen should be strictly observed to minimize the potential for severe hypotensive effects.


Adapted from the FDA Package Insert.

Template:WH Template:WS